Meta-analytic magic, ivermectin, and socially responsible reporting

Area of Science:

• Medical Ethics
• Infectious Diseases
• Pharmacology

Background:

• Ivermectin is prescribed for COVID-19 by some clinicians despite lacking support from South African professional bodies.
• The argument for its use centers on acting on weak efficacy signals during clinical urgency when harm is perceived as unlikely.

Purpose of the Study:

• To critically evaluate the evidence supporting ivermectin's use for COVID-19.
• To assess the implications of relying on weak or biased evidence in clinical decision-making during a pandemic.
• To emphasize the importance of evidence-based medicine (EBM) principles in medical practice.

Main Methods:

• Systematic review and meta-analysis of existing studies on ivermectin for COVID-19.
• Analysis of study bias and control types (active vs. placebo).
• Assessment of statistical significance of pooled mortality effects.

Main Results:

• Recent reviews including high-risk bias studies and active controls showed an apparent mortality benefit.
• Excluding these biased studies rendered the pooled mortality effect statistically insignificant.
• The evidence for ivermectin's benefit in treating COVID-19 is considered very weak.

Conclusions:

• Relying on weak evidence for ivermectin could lead to clinical harm and fuel vaccine hesitancy.
• Clinicians must ensure their guidance is legitimate and reliable, adhering to evidence-based medicine (EBM) principles.
• Medical institutions should promote EBM as a lifelong learning process for consistent, evidence-based debate in clinical practice.